Jazz Pharmaceuticals Newsroom

Jazz Pharmaceuticals Analyst Ratings

BenzingaJul 12 13:08 ET

Jazz Pharmaceuticals (JAZZ) Receives a Hold From Morgan Stanley

TipRanksJul 12 08:41 ET

RBC Trims Price Target on Jazz Pharmaceuticals to $175 From $176, Keeps Outperform Rating

MT NewswiresJul 9 08:03 ET

Jazz Pharmaceuticals Analyst Ratings

BenzingaJul 2 14:52 ET

Jazz Pharmaceuticals Analyst Ratings

BenzingaJun 20 11:21 ET

Jazz Pharmaceuticals Analyst Ratings

BenzingaJun 5 08:27 ET

UBS Adjusts Price Target on Jazz Pharmaceuticals to $117 From $121, Maintains Neutral Rating

MT NewswiresMay 3 12:02 ET

Jazz Pharmaceuticals Analyst Ratings

BenzingaMay 3 10:31 ET

Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Jazz Pharmaceuticals (JAZZ) and KalVista Pharmaceuticals (KALV)

TipRanksMay 3 06:40 ET

RBC Capital Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

TipRanksMay 2 06:51 ET

Jazz Pharmaceuticals Analyst Ratings

BenzingaMay 2 06:37 ET

Buy Rating Affirmed: Jazz Pharmaceuticals' Resilient Base and Promising Pipeline Drive Positive Outlook

TipRanksMay 2 06:15 ET

Barclays Remains a Buy on Jazz Pharmaceuticals (JAZZ)

TipRanksMay 1 04:00 ET

Jazz Pharmaceuticals (JAZZ) Gets a Buy From Barclays

TipRanksApr 23 06:01 ET

Jazz Pharmaceuticals Analyst Ratings

BenzingaApr 10 09:38 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ)

TipRanksApr 8 22:06 ET

JPMorgan Raises Jazz Pharmaceuticals' Price Target to $190 From $170, Maintains Overweight Rating

MT NewswiresMar 25 14:16 ET

Jazz Pharmaceuticals Analyst Ratings

BenzingaMar 22 13:50 ET

Optimistic Outlook on Jazz Pharmaceuticals' Zanidatamab Across Multiple Cancer Types: A Buy Rating Analysis

TipRanksMar 21 02:25 ET

Buy Rating Affirmed for Jazz Pharmaceuticals on Strong Zanidatamab Revenue Prospects and Clinical Milestones

TipRanksMar 20 06:50 ET